Opthea Limited to Present Phase 3 Trial Data at 43rd Annual J.P. Morgan Healthcare Conference

Opthea will present Phase 3 trial updates at the J.P. Morgan Healthcare Conference on January 15, 2025.

Quiver AI Summary

Opthea Limited, a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases, announced that its CEO, Frederic Guerard, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2025, at 5:15 PM PT. The presentation will include an update on the company, revealing masked patient demographics and baseline characteristics from the Phase 3 pivotal trials of their lead candidate, sozinibercept, aimed at treating wet age-related macular degeneration (wet AMD). The executive team will also be available for one-on-one meetings during the conference from January 13-16, 2025. The presentation will be available live and subsequently as a replay on their website.

Potential Positives

• Opthea is presenting significant updates at a prominent healthcare conference, which enhances visibility and credibility in the biopharmaceutical industry.
• The announcement includes the reveal of masked Phase 3 patient demographics and baseline characteristics, which can provide valuable insights into the progression of clinical trials for sozinibercept.
• Engagement in one-on-one meetings at the conference may attract potential investors and collaborators, facilitating future partnerships and funding opportunities.

Potential Negatives

• Details on patient demographics and baseline characteristics are masked, which may raise concerns about the transparency and completeness of the Phase 3 trial data.
• The presentation mainly focuses on Phase 3 trial updates, indicating an ongoing reliance on trial results for advancement, which may be seen as a sign of vulnerability or uncertainty in product development timelines.

FAQ

What is the date and time of the J.P. Morgan Healthcare Conference presentation?

The presentation is on January 15, 2025, at 5:15 PM PT.

Who will be presenting at the conference?

Frederic Guerard, PharmD, Chief Executive Officer of Opthea, will present at the conference.

What topic will be discussed during the presentation?

The presentation will cover masked Phase 3 patient demographics and baseline characteristics from the sozinibercept trials.

Where can I watch the live webcast of the presentation?

The live webcast will be available on the "Events & Presentations" section of Opthea’s website.

How long will the presentation replay be available?

The replay of the presentation will be available for 30 days after the event.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$OPT Hedge Fund Activity

We have seen 4 institutional investors add shares of $OPT stock to their portfolio, and 7 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• VICTORY CAPITAL MANAGEMENT INC removed 840,040 shares (-100.0%) from their portfolio in Q3 2024
• TEACHER RETIREMENT SYSTEM OF TEXAS removed 269,399 shares (-100.0%) from their portfolio in Q3 2024
• BANK OF MONTREAL /CAN/ removed 48,618 shares (-100.0%) from their portfolio in Q3 2024
• JANE STREET GROUP, LLC added 26,632 shares (+inf%) to their portfolio in Q3 2024
• TWIN LAKES CAPITAL MANAGEMENT, LLC added 19,806 shares (+inf%) to their portfolio in Q3 2024
• ROYAL BANK OF CANADA removed 6,000 shares (-100.0%) from their portfolio in Q3 2024
• MILLENNIUM MANAGEMENT LLC removed 3,777 shares (-5.3%) from their portfolio in Q3 2024

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

Business update to include masked Phase 3 patient demographics and baseline characteristics

Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California

MELBOURNE, Australia and PRINCETON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at the 43

^rd

Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 15, 2025 at 5:15 PM PT.

Dr. Guerard will provide an update on the business, including masked patient demographics and baseline characteristics from the sozinibercept Phase 3 wet AMD pivotal trials. Opthea’s executive team will attend the conference and be available for one-on-one meetings January 13-16, 2025.

The live webcast and presentation will be accessible on the “Events & Presentations” section of the Company’s website at

http://ir.opthea.com/

, where the replay will be available for 30 days.

About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST,

NCT04757636

, and ShORe,

NCT04757610

) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website at

www.opthea.com

and follow us on

X

and

LinkedIn

.

Authorized for release to ASX by Frederic Guerard, PharmD, CEO

Join our email database to receive program updates:


Tel: +61 (0) 3 9826 0399, Email:


info@opthea.com


Web:


www.opthea.com

Source: Opthea Limited

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.